ZHONGZE Therapeutics is a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders. A pioneer in neuroplasticity hypothesis-based drug discovery and precision neurology, Zhongze Therapeutics integrates target- and phenotypic-based drug discovery with precision neurology approaches to discover and develop effective CNS therapies more efficiently.
ZHONGZE has a robust pipeline and a wide variety of validated targets and pathways for CNS diseases.. Our most advanced therapeutic compounds include a phase II combination drug for substance use disorders (addiction) and a phase I small molecule for schizophrenia. Top line results from a SAD study of ZZ6398 indicate it is safe and well tolerated in healthy human volunteers. In addition there are several additional clinical programs on the horizon with a number of ongoing preclinical programs.